Sarepta Therapeutics

YTD

ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

CEO

Douglas S. Ingram

CEODouglas S. Ingram

Employees

835

Employees835

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1980

Founded1980

Employees

835

Employees835

SRPT Key Statistics

Market cap

1.84B

Market cap1.84B

Price-Earnings ratio

-1.98

Price-Earnings ratio-1.98

Dividend yield

—

Dividend yield—

Average volume

2.70M

Average volume2.70M

High today

$17.65

High today$17.65

Low today

$16.57

Low today$16.57

Open price

$16.80

Open price$16.80

Volume

1.80M

Volume1.80M

52 Week high

$104.85

52 Week high$104.85

52 Week low

$10.42

52 Week low$10.42

Stock Snapshot

As of today, Sarepta Therapeutics(SRPT) shares are valued at $17.51. The company's market cap stands at 1.84B, with a P/E ratio of -1.98.

During the trading session on 2026-03-09, Sarepta Therapeutics(SRPT) shares reached a daily high of $17.65 and a low of $16.57. At a current price of $17.51, the stock is +5.7% higher than the low and still -0.8% under the high.

Trading volume for Sarepta Therapeutics(SRPT) stock has reached 1.8M, versus its average volume of 2.7M.

The stock's 52-week range extends from a low of $10.42 to a high of $104.85.

SRPT News

Simply Wall St 2d

Is Sarepta Therapeutics A Potential Opportunity After An 84% One-Year Share Price Fall

If you are wondering whether Sarepta Therapeutics is now a bargain or a value trap after its recent performance, you are not alone. The stock last closed at US...

Simply Wall St 3d

Sarepta Therapeutics Is Down 7.0% After CEO Retirement Plan And ELEVIDYS Japan Launch News - Has The Bull Case Changed?

In late February 2026, Sarepta Therapeutics reported fourth-quarter 2025 revenue of US$442.93 million and a net loss of US$412.23 million, alongside CEO Douglas...

Simply Wall St 4d

A Look At Sarepta Therapeutics Valuation After Elevidys Launch Updates And Recovery Story Analyst Commentary

Sarepta Therapeutics (SRPT) is back in focus after recent analyst commentary framed the company as a potential recovery story, highlighting Elevidys launch effo...

Analyst ratings

54%

of 24 ratings

Buy

29.2%

Hold

54.2%

Sell

16.7%

More SRPT News

TipRanks 6d

Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty

Sarepta Therapeutics Inc. (SRPT) has disclosed a new risk, in the Corporate Activity and Growth category. Sarepta Therapeutics Inc. faces execution risk around...

TipRanks 7d

Sarepta Therapeutics Eyes 2026 Reset After Rocky Year

Sarepta Therapeutics Inc. ((SRPT)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-...

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.